Author Archives: admin

Cell Therapy Technologies Market Projected to Reach Valuation of USD 47.3 Billion at 24.7% CAGR from 2024-2033 … – GlobeNewswire

By adminJanuary 16, 2024Stem Cell Treatment

New York, Jan. 16, 2024 (GLOBE NEWSWIRE) -- In 2023Cell therapy technologiesmarket were valued at USD 5.5 billion in 2023 with significant growth and are projected to reach USD 47.3 billion by 2033 with an outstanding CAGR of 24.7%.

The surge in demand for advanced diagnostic tools and therapeutic interventions is pushing the cell therapy technology market forward. Cell therapy, a main element in treating regenerative medicines, has become extensively popular, particularly in regenerative medicine. Combined with other equipment like Platelet-Rich plasma (PRP), cell therapy improves its power and effectiveness, proposing extra benefits to patients.

Get additional highlights on major revenue-generating segments, Request a Cell Therapy Technologies Market sample report at https://marketresearch.biz/report/cell-therapy-technologies-market/request-sample/

Cell therapy comprises launching innovative, healthy cells into a patient's body, playing a vital role in handling certain cancers and neurological diseases such as Parkinson's, amyotrophic lateral sclerosis (ALS), and diabetes. With over 1 million individuals worldwide suffering from Parkinson's disease, a number projected to reach 1.2 million by 2030, cell therapy emerges as a promising solution. Likewise, ALS is predominant, mostly in Western Europe, where it has a prevalence rate of 9.62 per 1,000,000 populations.

The benefits of cell therapy technologies comprise pain reduction, augmented functionality, fast-tracked recovery, aid in complex injuries, and a reduced risk of nerve damage and communicable diseases. As these therapies display innovative diagnostic and treatment methods, the market is poised for rapid expansion to meet the cumulative requirement for transformative medical solutions during the forecasted period.

Key Takeaways

Driving Factors

Introduction of Innovative Products

These innovative products, crafted to meet the requirements of different patients, have been instrumental in the advancement of cell therapies. This trend of continual product innovation is essential for keeping pace with the evolving demands of healthcare, ensuring the market's resilience and adaptability. The focus on innovation drives market growth by providing more effective, efficient, and tailored treatment options, thereby enhancing patient outcomes and expanding the potential applications of cell therapies. The market is composed of unrelenting growth, reinforced by a pipeline of advanced transformative cell therapy technologies.

Enhanced Demographic and Environmental Dynamics

Population growth escalates the demand for innovative healthcare solutions, including cell therapies for diverse medical conditions. Climate change, influencing disease patterns and health vulnerabilities, further propels the need for advanced treatments. These key factors collectively drive the development and adoption of cell therapy technologies, as they offer targeted and efficient treatment options for an array of health issues emerging in this changing global landscape.

To understand how our report can bring a difference to your business strategy, Inquire about a brochure at https://marketresearch.biz/report/cell-therapy-technologies-market/#inquiry

Restraining Factors

Cost and Reimbursement Issues

Cell therapy treatments are typically associated with high costs, both in terms of production and administration. The problem of reimbursement and costs is crucial to the development of the cell-based therapy business. Furthermore, the lack of clear reimbursement pathways adds to the complexity as insurers grapple with how to classify and cover these novel treatments. This makes them financially out of reach for many patients and healthcare systems. These financial hurdles not only limit patient access but also deter investment and innovation in the field, as developers and benefactors face vagueness about the return on their significant funds in these advanced therapies.

Growth Opportunities

Increased Interest in customized medicines

Personalized medicine's approach of tailoring treatments to individual patients aligns perfectly with the capabilities of cell therapies. These therapies' adaptability to patient-specific needs positions them at the forefront of innovative treatments for a variety of medical conditions. This illustrates the growing significance of technology in the realm of personalized healthcare in the upcoming era of cell therapy. As healthcare continues to evolve towards more personalized strategies, the demand for cell therapy technologies is expected to rise, bolstered by their potential to provide targeted, patient-specific treatments.

Have Queries? Speak to an expert or To Download/Request a Sample, Click here.

Regional Analysis

North America rules the cell therapy technologies market, holding 55.60% due to robust research infrastructure, substantial biotech investments, and favorable policies. The U.S. leads with ground-breaking biotech firms and supportive government initiatives. Europe, compelled by research and regulatory support, sees contributions from Germany, the UK, and France. In Asia-Pacific, prompt market growth results from augmented healthcare investments and biomedical research, particularly in Japan and South Korea. The region's large population and rising chronic diseases present substantial opportunities for expanding cell therapy technologies.

Segment Analysis

By therapy type, Autologous therapies rule the market segment due to their substantial role in treatments utilizing cells. This method is widely used in various treatments, including certain types of cancer therapies, where patients' cells are engineered to fight cancer cells more effectively. Through the use of donors' cells, allogeneic therapies can play a significant role in treatments utilizing cells. The most significant benefit of autologous treatment is that there is less possibility that the immune system will reject it and related complications since the cells are derived from patients themselves. These therapies have the advantage of being available off-the-shelf, making them more accessible and sometimes more cost-effective.

By cell type, stem cells dominate the market segment due to their extensive use in hematopoietic stem cell transplantation for blood and bone marrow disorders. Stem cells ability to differentiate into various cell types makes them incredibly valuable in regenerative medicine and the treatment of various diseases. Adipose-derived stem cells are being explored for their potential in regenerative therapies due to their abundance and ease of extraction. Non-stem cell therapies, while not as adaptable as stem cells, are important in precise therapeutic applications, predominantly in certain types of cancer treatments where immune cells are contrived to target cancer cells.

By cell therapy therapeutic area type, oncology leads the market segment due to the effectiveness of cell therapy in treating various types of cancers, particularly through approaches like CAR-T cell therapies, which have transformed cancer treatment. These therapies have shown remarkable results in certain types of blood cancer, leading to significant investment and research in expanding their application to other cancer types. In dermatology, cell therapies offer advanced treatment options for skin regeneration and healing. Other therapeutic areas like cardiovascular disease (CVD), musculoskeletal disorders, dermatology, and others are also significant. Cell therapies in CVD aim to regenerate damaged heart tissue, while in musculoskeletal disorders, they are used for tissue repair and pain management.

For more insights on the historical and Forecast market data from 2016 to 2033 - download a sample report at https://marketresearch.biz/report/cell-therapy-technologies-market/request-sample/

Segments Covered in this Report

By Therapy Type

By Cell Type

By Cell Therapy Therapeutic Area

By Geography

Grow your profit margin with Marketresearch.biz - Purchase This Premium Report at https://marketresearch.biz/purchase-report/?report_id=8948

Competitive Landscape Analysis

In the dynamic field of cell therapy technologies, industry front-runners such as Thermo Fisher Scientific, Danaher Corporation, Becton, Dickinson & Company, Merck KGaA, Lonza Group, Sartorius AG, FUJIFILM Irvine Scientific, and Avantor, Inc. play pivotal roles. Their inclusive product ranges and tactical focuses on innovation, accuracy, and amalgamation contribute significantly to advancing cell therapy research, manufacturing, and efficiency.

Key Market Players

Recent Developments

Browse More Related Reports

About Us:

MarketResearch.Biz (Powered by Prudour Pvt Ltd) specializes in in-depth market research and analysis and has been proving its mettle as a consulting and customized market research company, apart from being a much sought-after syndicated market research report-providing firm.MarketResearch.Bizprovides customization to suit any specific or unique requirement and tailor-made reports as per request. We go beyond boundaries to take analytics, analysis, study, and outlook to newer heights and broader horizons.

Follow Us on LinkedIn:https://www.linkedin.com/company/marketresearch-biz/ Follow Us on Facebook:https://www.facebook.com/marketresearch.biz Follow Us on Twitter:https://twitter.com/PrudourResearch

Here is the original post:
Cell Therapy Technologies Market Projected to Reach Valuation of USD 47.3 Billion at 24.7% CAGR from 2024-2033 ... - GlobeNewswire

Life Science Research Heads to the ISS on Axiom Mission 3 – ISS National Lab

By adminJanuary 16, 2024Stem Cell Treatment

KENNEDY SPACE CENTER (FL), January 10, 2024 More than two dozen investigations sponsored by the International Space Station (ISS) National Laboratory, many of which focus on the life sciences, will fly on Axiom Spaces third private astronaut mission to the orbiting laboratory. Axiom Mission 3 (Ax-3) aims to help expand a new era of privatized utilization of the space station that will bring value to humanity while enabling the development of a robust and sustainable market in low Earth orbit (LEO) by advancing research in microgravity.

Four astronauts are slated to launch on a SpaceX Falcon 9 rocket and Dragon spacecraft to the space station no earlier than Wednesday, January 17, at 5:11 p.m. EST from NASAs Kennedy Space Center in Florida. During a planned two-week mission, Axiom Spaces chief astronaut and former NASA astronaut Michael Lpez-Alegra (commander), Walter Villadei of Italy (pilot), Alper Gezeravc of Trkiye (mission specialist), and European Space Agency (ESA) project astronaut Marcus Wandt of Sweden (mission specialist) will conduct more than 30 experiments.

Building on years of foundational research performed in microgravity, a number of these investigations aim to utilize the unique LEO environment to better understand an array of biological processes, including how spaceflight affects the human body, the mechanisms behind certain diseases, and how stem cell research can help lead to the development of novel therapeutics.

Below are some highlights of the investigations launching on the Ax-3 mission:

Through these private astronaut missions, Axiom Space and the ISS National Lab partner to expand access to the unique microgravity environment for the benefit of humanity. Ax-3 represents the first all-European commercial mission to the space station, further expanding spaceflight opportunities to more countries, companies, and people. In addition to the projects highlighted above, Ax-3 includes a strong focus on the scientific portfolios of the European nations represented on this mission, seeking to enhance scientific knowledge gained for humanity.

Read more about these investigations and others launching on this mission in Axiom Spaces Research Overview and on the ISS National Lab Ax-3 launch page.

Download the high-resolution image for this release: Axiom-2 Launch

Media Contact: Patrick ONeill 904-806-0035 PONeill@ISSNationalLab.org

# # #

About the International Space Station (ISS) National Laboratory: The International Space Station (ISS) is a one-of-a-kind laboratory that enables research and technology development not possible on Earth. As a public service enterprise, the ISS National Laboratory allows researchers to leverage this multiuser facility to improve quality of life on Earth, mature space-based business models, advance science literacy in the future workforce, and expand a sustainable and scalable market in low Earth orbit. Through this orbiting national laboratory, research resources on the ISS are available to support non-NASA science, technology, and education initiatives from U.S. government agencies, academic institutions, and the private sector. The Center for the Advancement of Science in Space (CASIS) manages the ISS National Lab, under Cooperative Agreement with NASA, facilitating access to its permanent microgravity research environment, a powerful vantage point in low Earth orbit, and the extreme and varied conditions of space. To learn more about the ISS National Lab, visit our website.

As a 501(c)(3) nonprofit organization, CASIS accepts corporate and individual donations to help advance science in space for the benefit of humanity. For more information, visit our donations page.

About Axiom Space: Axiom Space is building for beyond, guided by the vision of a thriving home in space that benefits every human, everywhere. The leading provider of human spaceflight services and developer of human-rated space infrastructure, Axiom Space operates end-to-end missions to the International Space Station today while developing its successor, Axiom Station the worlds first commercial space station in low-Earth orbit, which will sustain human growth off the planet and bring untold benefits back home. For more information visit Axiom Spaces website.

Read the original post:
Life Science Research Heads to the ISS on Axiom Mission 3 - ISS National Lab

Sarah Irvine’s Battle with MS: The Hope of Stem Cell Treatment – BNN Breaking

By adminJanuary 16, 2024Stem Cell Treatment

Sarah Irvines Battle with MS: The Hope of Stem Cell Treatment

On a quiet street in a bustling city, Sarah Irvine lives a life that is far from ordinary. Diagnosed with a progressive form of multiple sclerosis (MS) in 2019, she faces a daily battle against her own body. In the midst of the turmoil, Sarah, like a beacon of resilience, is aspiring to undergo stem cell treatment in London, a decision that could potentially change the course of her life.

Multiple sclerosis is a debilitating condition where the immune system, in an uncharacteristic act of betrayal, turns against the nerve cells in the brain, spinal cord, and optic nerves. This internal assault can lead to severe impairments in mobility and other neurological functions, trapping individuals in a body that refuses to obey.

For Sarah, this is more than just medical jargon. Its her reality. Every day, she wakes up to a world where simple tasks become Herculean challenges and where the uncertainty of the future looms large. Yet, in the face of adversity, she stands undeterred, ready to fight.

In her quest to combat the impact of this disease, Sarah is setting her sights on a treatment that, while often seen as a last resort, holds the promise of potentially slowing down, or even halting, the progression of her MS symptoms. This treatment involves the transplantation of stem cells, tiny powerhouses of regeneration that may hold the key to resetting the immune system and halting its attack on the nervous system.

Sarahs journey is far from easy. The road to potential treatment is fraught with obstacles, each more daunting than the last. But her determination is unwavering. In her struggle, she becomes a symbol of resilience, a testament to the human spirits indomitable will to survive.

As Sarah navigates her path towards potential recovery, her story serves as a reminder of the ongoing struggle faced by individuals living with MS and the relentless search for effective therapies. In the midst of the battle, however, one thing remains clear: the spirit of the human will, as embodied by Sarah, remains unbroken, undeterred, and unstoppable.

A guide to stem cell therapy in Thailand – Thaiger

By adminJanuary 16, 2024Stem Cell Treatment

PHOTO: Stem Cell Therapy at Identity Clinic

You probably have heard about stem cell therapy and its ability to improve your quality of life and feel sceptical about it. While the procedure may sound like something out of science fiction, its actually a promising medical procedure with a wide range of benefits. In fact, it has grown in popularity and shown remarkable effectiveness over the past few years. Thailand has been quick to adapt stem cell therapy and is now leading the charge in Asia.

If youre thinking about getting stem cell therapy in Thailand, you probably have a lot of questions about it. What exactly is it? Is it the appropriate procedure for your condition? Can it really reverse ageing? Where should you head to in Thailand to receive this treatment? To answer some of your questions, we sat down with Dr. Puii and Josh from Identity Clinic Bangkok to get an insight into stem cell therapy in Thailand.

Before we go into details on stem cell therapy in Thailand, lets first talk about the basics.

Stem cell therapy is a newer medical procedure that uses the power of stem cells, which are unspecialized cells that provide new cells for your body as you grow, and replace specialised cells that are damaged or lost. Were born with these cells and they continue to multiply until we reach the age of around 20. After that, though, their numbers and effectiveness start to decline. At around the age of 30 to 35 years old, they take a significant dip in both quality and quantity. This reduction in stem cells is one reason why our bodies start showing signs of ageing.

Stem cells play a crucial role in our health, helping with growth, repair, and even tackling inflammation. Thats why stem cell therapy is a promising medical procedure to treat various medical conditions.

Stem cell therapy provides a wide range of benefits. While it can be used to treat a range of health conditions, stem cell therapy also makes its way into cosmetic treatments and wellness initiatives. Here are some of the main benefits of stem cell therapy that you can get in Identity Clinic Bangkok, Thailand:

Stem cell therapy offers a wide range of benefits for those seeking enhanced well-being.

One of the most popular benefits of stem cell therapy is skin rejuvenation. The therapy facilitates the healing of bruises, cuts, and other skin imperfections. In addition, it can also reduce wrinkles and increase the strength of your dermis the thick layer of living tissue that forms your true skin beneath the epidermis. Stem cell therapy restores the skin deep down to the cellular level, causing your skin to become brighter and tighter. Thus, youll feel refreshed and rejuvenated after each treatment.

In addition to enhancing your immune system, this cutting-edge treatment can also positively impact your sleep quality, which in turn will boost your overall energy levels. Research by DVC Stem reveals that patients undergoing stem cell therapy have reported impressive results, with a notable 75% increase in stamina and a significant 51.40% improvement in energy levels 3 months after treatment.

Stem cell therapy can improve your cognitive function, such as memory and decision-making abilities. Plus, it can make a big difference in how well your nerves send signals to your muscles, which means it can enhance your motor functions.

Youd be amazed to know how much your blood work can benefit from consistent stem cell therapy. Over time, this can also boost the performance of your kidneys and liver, and generally enhance the health of all your organs.

Stem cell therapy in Identity Clinic Bangkok, Thailand can also be used as targeted treatment for specific conditions.

If youve been dealing with knee pain, stem cell therapy may be able to regenerate your knee joints due to arthritis, traumatic ligament injuries, and degenerative conditions.

Stem cell therapy has shown promise in slowing down dementia, such as Alzheimers disease. This is achieved by substituting impaired cells with robust ones, enhancing memory functionality, and regenerating neurons.

Erectile dysfunction, the inability to keep an erection, can be treated with stem cell therapy. With this therapy, the stem cells act as a muscle inside the penis, thereby rejuvenating its tissues and restoring their functionality.

Stem cell therapy is a breakthrough in the treatment of Crohns disease. It has the potential to lessen intestinal inflammation, foster the recovery of the intestinal lining, and enhance your overall life quality.

According to Dr. Puii, another significant benefit of stem cell therapy is helping individuals with pathological conditions like diabetes, hypertension, and heart conditions. Stem cell therapy becomes a continuous treatment option for those seeking to improve and manage their conditions.

Beyond adult treatments, stem cell therapy shows promise in treating chronic diseases in children, such as cerebral palsy, mental disorders, and movement abnormalities. The therapy offers hope for improving conditions that persist into adulthood.

If youve been reading about stem cell therapy, youre probably aware that there are misconceptions surrounding it, causing confusion and fear. One prevalent misconception suggests that stem cell therapy can increase your risk of cancer. There have been no reports of the therapy causing cancer, but to mitigate potential risks, its essential to get this treatment from trusted clinics that use approved stem cells.

Another misconception about stem cells is that they may lead to the growth of extra limbs. Its crucial to clarify that such fantastical claims lack scientific basis. Stem cell therapy, when administered responsibly, adheres to stringent safety standards and does not result in abnormal cell proliferation or limb regeneration.

Its important to remember that while stem cell therapy isnt a universal solution, its not a harmful procedure. Stem cell therapy doesnt reverse ageing or prompt the growth of additional body parts. Instead, its focus is on aiding the bodys natural healing processes and enhancing overall well-being.

There are many medical centres across Thailand offering stem cell therapy, but not all of them are the same. Just like any other healthcare procedure, the most important thing when it comes to stem cell therapy is choosing the right clinic. Be sure to verify that the doctors and staff are well-versed in the procedure and that the clinic is committed to advancing their stem cell therapy technology, This ensures you receive the best possible treatment with a high success rate.

One of the leading clinics offering stem cell therapy in Thailand is Identity Clinic. With top-notch stem cell banks, world-class laboratories, and VIP rooms, the clinic ensures clients receive a royal and unmatched experience. Heres what Identity Clinic offers to their patients:

What sets Identity Clinic apart is its commitment to high-quality stem cells. They use Mesenchymal Stem Cells (MSCs) from the umbilical cord that are carefully screened for health conditions by world-class certified labs and the US FDA. Moreover, these stem cells come with extensive certifications, blood work, and detailed reports. The clinic uses an ID Barcode system to ensure accuracy and traceability. Therefore, clients have full transparency about the stem cells they receive.

Identity Clinic boasts certifications from esteemed global institutions. These include the American Association of Blood Banks (AABB) standards, a recognition highly esteemed by medical organisations worldwide, particularly those in the United States. The clinic also holds the ISO 9001 certification and uses US FDA-approved medical equipment to provide the best and safest procedures for their patients. Furthermore, the clinic has been honoured with the European Society for Quality Research award from Germany, a prestigious recognition given to organisations that demonstrate exceptional quality and ethical practices.

Patients at Identity Clinic enjoy a luxurious and comfortable experience. From the customer service to the interior, the clinic ensures a premium healthcare journey. The staff goes the extra mile to meet all of your needs. Moreover, the treatment rooms are designed to promote both physical comfort and peace of mind as you undergo stem cell therapy.

Identity Clinic takes pride in staying at the forefront of stem cell research and therapy. The dedicated team, led by renowned doctors like Dr. Shin and Dr. Puii, continuously studies and integrates the latest advancements in stem cell treatment.

Stem cell therapy can work wonders in addressing a wide range of medical conditions. And Identity Clinic is dedicated to offering stem cell therapies for all kinds of patients, including those seeking skin rejuvenation. They combine stem cell therapy with state-of-the-art skin treatments like laser procedures and Thermage. This integrated approach not only enhances overall health but also greatly improves skin texture and appearance, adding a youthful glow like never before.

At Identity Clinic, stem cell therapy is not a one-size-fits-all treatment. They offer personalised care plans for various health conditions to make sure that every patient receives positive and sustained effects from their stem cell therapy. To achieve this, they perform a series of preliminary medical evaluations on every new patient prior to beginning their treatment. Among these tests, checking for allergies and carrying out comprehensive assessments for potential underlying medical conditions are essential parts of their preparation protocol.

If youre curious about the potential benefits of stem cell therapy, be sure to contact Identity Clinic for more information. With a focus on quality, certifications, and personalised care plans, the clinic ensures a top-notch experience for every patient.

Clinical applications of stem cell-derived exosomes | Signal Transduction and Targeted Therapy – Nature.com

By adminJanuary 16, 2024Embryonic Stem Cells

Kimbrel, E. A. & Lanza, R. Next-generation stem cells - ushering in a new era of cell-based therapies. Nat. Rev. Drug. Discov. 19, 463479 (2020).

Article CAS PubMed Google Scholar

Puri, M. C. & Nagy, A. Concise review: embryonic stem cells versus induced pluripotent stem cells: the game is on. Stem Cells. 30, 1014 (2012).

Article CAS PubMed Google Scholar

Ng, A. P. & Alexander, W. S. Haematopoietic stem cells: past, present and future. Cell Death Discov. 3, 17002 (2017).

Article PubMed PubMed Central Google Scholar

Naji, A. et al. Biological functions of mesenchymal stem cells and clinical implications. Cell Mol. Life Sci. 76, 33233348 (2019).

Article CAS PubMed Google Scholar

Tang, Y., Yu, P. & Cheng, L. Current progress in the derivation and therapeutic application of neural stem cells. Cell Death Dis. 8, e3108 (2017).

Article CAS PubMed PubMed Central Google Scholar

Chambers, S. E. J. et al. Current concepts on endothelial stem cells definition, location, and markers. Stem Cells Transl. Med. 10, S54S61 (2021).

Article PubMed PubMed Central Google Scholar

Hoang, D. M. et al. Stem cell-based therapy for human diseases. Signal Transduct. Target Ther. 7, 272 (2022).

Article PubMed PubMed Central Google Scholar

Zakrzewski, W., Dobrzynski, M., Szymonowicz, M. & Rybak, Z. Stem cells: past, present, and future. Stem Cell Res. Ther. 10, 68 (2019).

Article CAS PubMed PubMed Central Google Scholar

Zhang, K. & Cheng, K. Stem cell-derived exosome versus stem cell therapy. Nat. Rev. Bioeng. 1, 608609 (2023).

Article Google Scholar

Zhang, Y. et al. Exosome: A Review Of Its Classification, Isolation Techniques, Storage, Diagnostic And Targeted Therapy Applications. Int. J. Nanomed. 15, 69176934 (2020).

Article CAS Google Scholar

Vizoso, F. J. et al. Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine. Int. J. Mol. Sci. 18, 18521875 (2017).

Article PubMed PubMed Central Google Scholar

Ren, K. Exosomes in perspective: a potential surrogate for stem cell therapy. Odontology. 107, 271284 (2019).

Article CAS Google Scholar

Hastuti, S. et al. hUMSC vs. hUMSC-Exosome: which one is better for epilepsy? Pharmaceuticals. 15, 12471261 (2022).

Article CAS PubMed PubMed Central Google Scholar

Carr, N. J. The pathology of healing and repair. Surgery 40, 1319 (2022).

Google Scholar

Peshkova, M. et al. Targeting inflammation and regeneration: scaffolds, extracellular vesicles, and nanotechnologies as cell-free dual-target therapeutic strategies. Int. J. Mol. Sci. 23, 1379613813 (2022).

Article CAS PubMed Central Google Scholar

Wang, H., Huber, C. C. & Li, X. P. Mesenchymal and neural stem cell-derived exosomes in treating alzheimeras disease. Bioengineering 10, 253266 (2023).

Article CAS PubMed PubMed Central Google Scholar

Li, X. et al. Neural stem/progenitor cell-derived extracellular vesicles: a novel therapy for neurological diseases and beyond. MedComm 4, e214 (2023).

Article CAS PubMed Central Google Scholar

Norouzi-Barough, L., Shirian, S., Gorji, A. & Sadeghi, M. Therapeutic potential of mesenchymal stem cell-derived exosomes as a cell-free therapy approach for the treatment of skin, bone, and cartilage defects. Connect Tissue Res. 63, 8396 (2022).

Article CAS Google Scholar

Doyle, L. M. & Wang, M. Z. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells. 8, 727750 (2019).

Article CAS PubMed PubMed Central Google Scholar

Pegtel, D. M. & Gould, S. J. Exosomes. Annu. Rev. Biochem. 88, 487514 (2019).

Article CAS PubMed Google Scholar

Gurung, S., Perocheau, D., Touramanidou, L. & Baruteau, J. The exosome journey: from biogenesis to uptake and intracellular signalling. Cell Commun. Signal. 19, 47 (2021).

Article CAS PubMed PubMed Central Google Scholar

Zhang, Y., Liu, Y., Liu, H. & Tang, W. H. Exosomes: biogenesis, biologic function and clinical potential. Cell Biosci. 9, 19 (2019).

Article PubMed PubMed Central Google Scholar

Gholami Farashah, M. S. et al. Bone marrow mesenchymal stem cells exosomes as key nanoparticles in osteogenesis and bone regeneration: specific capacity based on cell type. Mol. Biol. Rep. 49, 1220312218 (2022).

Article CAS PubMed Google Scholar

Qing, L., Chen, H., Tang, J. & Jia, X. Exosomes and their MicroRNA cargo: new players in peripheral nerve regeneration. Neurorehabilit. Neural Repair. 32, 765776 (2018).

Article Google Scholar

Kwok, Z. H., Wang, C. & Jin, Y. Extracellular vesicle transportation and uptake by recipient cells: a critical process to regulate human diseases. Processes 9, 273294 (2021).

Article CAS PubMed Google Scholar

Kimiz-Gebologlu, I. & Oncel, S. S. Exosomes: large-scale production, isolation, drug loading efficiency, and biodistribution and uptake. J. Control Release 347, 533543 (2022).

Article CAS PubMed Google Scholar

Hamzah, R. N., Alghazali, K. M., Biris, A. S. & Griffin, R. J. Exosome traceability and cell source dependence on composition and cell-cell cross talk. Int. J. Mol. Sci. 22, 53465362 (2021).

Article CAS PubMed PubMed Central Google Scholar

Li, M. et al. Exosomes from different cells: characteristics, modifications, and therapeutic applications. Eur. J. Med. Chem. 207, 112784 (2020).

Article CAS PubMed Google Scholar

Shan, X. et al. The biogenesis, biological functions, and applications of macrophage-derived exosomes. Front. Mol. Biosci. 8, 715461 (2021).

Article CAS PubMed PubMed Central Google Scholar

Wang, Y. et al. Macrophage-derived extracellular vesicles: diverse mediators of pathology and therapeutics in multiple diseases. Cell Death Dis. 11, 924 (2020).

Article CAS PubMed PubMed Central Google Scholar

Liu, J., Wu, F. & Zhou, H. Macrophage-derived exosomes in cancers: biogenesis, functions and therapeutic applications. Immunol. Lett. 227, 102108 (2020).

Article CAS Google Scholar

Elashiry, M., Elsayed, R. & Cutler, C. W. Exogenous and endogenous dendritic cell-derived exosomes: lessons learned for immunotherapy and disease pathogenesis. Cells. 11, 115136 (2021).

Article PubMed PubMed Central Google Scholar

Pitt, J. M. et al. Dendritic cell-derived exosomes for cancer therapy. J Clin Investig. 126, 12241232 (2016).

Article PubMed Central Google Scholar

Kok, V. C. & Yu, C. C. Cancer-derived exosomes: their role in cancer biology and biomarker development. Int. J. Nanomed. 15, 80198036 (2020).

Article CAS Google Scholar

Naseri, M. et al. Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy. Oncoimmunology 9, 1779991 (2020).

Article PubMed PubMed Central Google Scholar

Kluszczynska, K. et al. Methods for the determination of the purity of exosomes. Curr. Pharm. Des. 25, 44644485 (2019).

Article CAS PubMed Google Scholar

Zhou, B. et al. Application of exosomes as liquid biopsy in clinical diagnosis. Signal Transduct Target Ther. 5, 144 (2020).

Article CAS PubMed Central Google Scholar

Boukouris, S. & Mathivanan, S. Exosomes in bodily fluids are a highly stable resource of disease biomarkers. Proteomics Clin. Appl. 9, 358367 (2015).

Article CAS PubMed PubMed Central Google Scholar

Gurunathan, S. et al. Review of the isolation, characterization, biological function, and multifarious therapeutic approaches of exosomes. Cells. 8, 307342 (2019).

Article CAS PubMed Central Google Scholar

Bei, H. P. et al. Bone-a-Petite: engineering exosomes towards Bone, osteochondral, and cartilage repair. Small. 17, e2101741 (2021).

Article PubMed Google Scholar

Yang, X. X., Sun, C., Wang, L. & Guo, X. L. New insight into isolation, identification techniques and medical applications of exosomes. J. Control Release 308, 119129 (2019).

Article CAS PubMed Google Scholar

Kalluri, R. & LeBleu, V. S. The biology, function, and biomedical applications of exosomes. Science. 367, 640654 (2020).

Article Google Scholar

Li, X. et al. Challenges and opportunities in exosome research-Perspectives from biology, engineering, and cancer therapy. APL Bioeng. 3, 011503 (2019).

Article PubMed PubMed Central Google Scholar

Khayambashi, P. et al. Hydrogel encapsulation of mesenchymal stem cells and their derived exosomes for tissue engineering. Int. J. Mol. Sci. 22, 684698 (2021).

Article CAS PubMed PubMed Central Google Scholar

Hussen, B. M. et al. Strategies to overcome the main challenges of the use of exosomes as drug carrier for cancer therapy. Cancer Cell Int. 22, 323 (2022).

Article PubMed PubMed Central Google Scholar

Shao, J., Zaro, J. & Shen, Y. Advances in exosome-based drug delivery and tumor targeting: from tissue distribution to intracellular fate. Int. J. Nanomed. 15, 93559371 (2020).

Article CAS Google Scholar

Tian, Y. et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 35, 23832390 (2014).

Article CAS Google Scholar

Kim, M. S. et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine 12, 655664 (2016).

Article CAS PubMed Google Scholar

Ohno, S. et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 21, 185191 (2013).

Article CAS PubMed Google Scholar

Alvarez-Erviti, L. et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29, 341345 (2011).

Article CAS PubMed Google Scholar

More:
Clinical applications of stem cell-derived exosomes | Signal Transduction and Targeted Therapy - Nature.com

Developing in-vivo chimeric lungs with pluripotent stem cells – Drug Target Review

By adminJanuary 16, 2024Embryonic Stem Cells

Reverse-blastocyst complementation elucidates the conditions required to form lungs in rat-mouse chimeric models.

Researchers from the Nara Institute of Science and Technology (NAIST) have used the reverse-blastocyst complementation (rBC) method to understand the conditions required to form lungs in rat-mouse chimeric models. They also used the tetraploid-based organ complementation (TOC) method to create a rat-derived lung in their mouse model.

Chronic obstructive pulmonary disease (COPD) is the third leading cause of global deaths. The pathogenesis of COPD is based on the innate and adaptive inflammatory immune response to the inhalation of toxic particles and gases. Although tobacco smoking is the primary cause of this inhalation injury, many other environmental and occupational exposures contribute to the pathology of COPD.1

Lung transplantation is the only viable treatment option, yet finding suitable lung donors is difficult. However, regenerative medicine is advancing the development of lungs from pluripotent stem cells (PSCs) using interspecies animal models. Current expectations for realisation of the promise of PSCs are at the highest they have ever been. However, there are many challenges that need to be addressed in order to bring PSC technology within the grasp of many more patients. Three particular challenges are: tumorigenicity, immunogenicity, and heterogeneity.2

PSCs and embryonic stem cells (ESCs) from one species can be injected into blastocytes, the cluster of diving cells made by a fertilised egg, in a biological technique named blastocyst complementation to create interspecies chimeric animals. This has enabled successful regeneration of the heart, pancreas and kidney in rat-mouse chimeras, but functional lung formation remains to be achieved successfully in vitro due to the complex three-dimensional (3D) structures and multiple cell types needed. This has warranted more research into the viable conditions required to generate PSC-derived organs.

Fibroblast growth factors (FGFs)are polypeptides with various biological activities bothin vivoandin vitro.3 The fibroblast growth factor 10 (Fgf10) and its interaction with the Fgf receptor isoform IIIb (Fgfr2b) in the lungs are essential for lung development. The rBC method in the new study involved injecting mutant ESCs which fail to show lung formation into wild-type (WT) embryos. This allowed for efficient detection of mutant PSCs in the recipient tissue, aiding the determination of the conditions necessary for successful lung formation in the organ-deficient animal.

The team, led by Dr Shunsuke Yuri and Dr Ayako Isotani, discovered that WT ESCs provide uniform contributions across target and non-target organs in the chimeras. This helped to ascertain that a particular number of WT or normal cells are required to overcome the lung development failure in Fgf10-deficient or Fgfr2b-deficient animals.

Having this understanding enabled them to produce rat-derived lungs in the Fgfr2b-deficient mouse embryos with the TOC method, without the requirement of producing a mutant mouse line. Dr Yuri said: Interestingly, we found that the rat epithelial cells conserved intrinsic species-specific timing in the interspecies model, resulting in an underdeveloped lung. Consequently, these lungs remained nonfunctional post-birth.

The studys findings identified the factors required for the successful generation of functional lungs in rat-mouse interspecies chimeras, as well as the issues to overcome. Dr Yuri concluded: We believe that our study makes an important contribution to the literature by presenting a faster and more efficient method of exploring blastocyst complementation.

These novel results can significantly advance the progress toward developingin-vivochimeric lungs for the purpose of transplantation, which could transform the practical application of regenerative medicine.

This study was published in Development.

1 Hogg JC, Timens W. The Pathology of Chronic Obstructive Pulmonary Disease. Annual Review of Pathology: Mechanisms of Disease. 2008 October 27 [2024 January 5]; 4:435-459. Available from: https://doi.org/10.1146/annurev.pathol.4.110807.092145

2 Yamanaka S. Pluripotent Stem Cell-Based Cell Therapy Promise and Challenges. Cell Stem Cell. 2020 October 1 [2024 January 5]; 27(4):523-31. Available from: https://doi.org/10.1016/j.stem.2020.09.014

3 Birnbaum D, Coulier F, Emoto H, Itoh N, Mattei MG, Tagashira S. Structure and Expression of Human Fibroblast Growth Factor-10*. Journal of Biological Chemistry. 1997 September [2024 January 2024]; 272(37):23191-4. Available from: https://doi.org/10.1074/jbc.272.37.23191

View original post here:
Developing in-vivo chimeric lungs with pluripotent stem cells - Drug Target Review

No, Rep. Steve Scalise Didn’t Vote Against Stem Cell Research From Which He Is Now Benefiting – Yahoo News

By adminJanuary 16, 2024Embryonic Stem Cells

A long-dormant medical controversy was revived last week following an announcement from House Majority Leader Steve Scalise. On January 5, his office released a statement indicating that he was undergoing a stem cell transplant as part of his previously announced treatment for multiple myeloma. Hearkening back to the stem cell controversies of the early 2000s, a number of posts emerged onlineincluding a viral Reddit thread and tweet with 54,000 likes and almost 10,000 retweetsaccusing the congressman of hypocrisy for receiving a treatment that he allegedly fought against.

The treatment Scalise is receiving has no relation to the embryonic stem cell research often opposed by pro-life Americans, however, and the congressman has never voted to restrict research into the form of treatment he is receiving.

Scalise first announced his diagnosis of multiple myelomaa rare blood cancerin late August 2023, telling reporters a month later that his body had responded well to his first round of treatment. The good news is the cancer has dropped dramatically because of the success of the chemotherapy, he said in September. The next step for Scalise, as mentioned above, is an autologous stem cell transplant. [Rep. Scalise] is currently undergoing the transplant process, marking a significant milestone in his battle against cancer, his offices January 5 statement read. Once the procedure is completed, he will be recovering under the supervision of his medical team and will work remotely until returning to Washington next month. Scalise is receiving treatment in his home state of Louisiana.

Because multiple myeloma attacks a patients bone marrowan essential tissue for the bodys production of blood cellsstem cell transplants are often used to help replace marrow damaged by the cancer with new and healthy marrow. In a typical autologous stem cell treatment, the kind which Scalise is receiving, a patients own hematopoietic stem cells are extracted and frozen multiple weeks before treatment. These cells used to be extracted from the bone marrow itself, but today most patients are given a growth factor that allows for stem cells to be taken directly from the blood. The patient is then given intensive chemotherapy, often in a single large dose, before receiving a transfusion of his or her own healthy stem cells. It then takes two to three weeks for the transfused stem cells to restore the functionality of the bone marrow, during which patients can be substantially immunocompromised because of their bodies inability to produce the white blood cells necessary for proper immune function.

Unlike embryonic stem cells, which are harvested from early stage human embryos and can take the form of any cell in the body, the hematopoietic stem cells used in the treatment of multiple myeloma are extracted from a patients own body or from a voluntary donor and can develop into only a limited range of blood cells. These are not the type of stem cells that are in an embryo that can become anything, Dr. Marc Braunstein, a hematology and stem cell transplant expert at NYU Langone Health, told The Dispatch Fact Check. These are slightly differentiated stem cells that are destined to become blood cells, but not anything else.

Traditional stem cell therapies are widely accepted and utilized in modern medical practice, unlike the embryonic stem cell research that reached a point of national controversy in the mid-2000s. We can debate the ethics of using embryonic stem cells, Braunstein said, but I think in this case were not talking about that at all. According to Braunstein, even patients who are practicing Jehovahs Witnessa religious group that typically rejects the use of blood transfusionsare often not opposed to autologous stem cell treatments. For those individuals who may be leery about the use of embryonic stem cells, I dont think they would be as concerned with the use of adult hematopoietic stem cells, Braunstein said.

Furthermore, Scalise has not taken any notable votes against stem cell researchembryonic or non-embryonic. Two notable bills intended to advance embryonic stem cell research, the Stem Cell Research Enhancement Act of 2005 and Stem Cell Research Enhancement Act of 2007, passed both the House and Senate, but both were vetoed by then President George W. Bush. These votes occurred prior to Scalise assuming office in May 2008, however, and very little legislative activity involving embryonic stem cell research has happened since.

In September 2020, Scalise co-signed a letter by Mississippi Sen. Roger Wicker calling for an end to taxpayer funded embryonic stem cell research at the National Institutes of Health, but the letter expressed no opposition to non-embryonic stem cell research or treatment. In fact, Scalise voted in favor of the Stem Cell Therapeutic and Research Reauthorization Act of 2010, Stem Cell Therapeutic and Research Reauthorization Act of 2015, and TRANSPLANT Act of 2021, all of which reauthorized a program intended to support patients in need of stem cell transplants.

Asked by The Dispatch Fact Check whether they believed allegations of hypocrisy were unfair, Scalises office declined to comment further, instead saying that the statement on his treatment spoke for itself.

If you have a claim you would like to see us fact check, please send us an email at factcheck@thedispatch.com. If you would like to suggest a correction to this piece or any other Dispatch article, please email corrections@thedispatch.com.

ROR2 expression predicts human induced pluripotent stem cell differentiation into neural stem/progenitor cells and … – Nature.com

By adminJanuary 8, 2024Induced Pluripotent Stem Cells

Cell culture

Commercially available hiPSC lines were used in this study (Supplementary Table 1). HiPSC lines were obtained from RIKEN Cell Bank (201B7, 253G1, 409B2, HiPS-RIKEN-1A, HiPS-RIKEN-2A, and HiPS-RIKEN-12A), American Type Culture Collection (ATCC-DYR0110 hiPSC and ATCC-HYR01103 hiPSC), JCRB Cell Bank (Tic), and System Biosciences (human mc-iPS). HiPSCs were screened for mycoplasma contamination and hiPSCs used in this study were mycoplasma-free. Undifferentiated hiPSCs were maintained on an iMatrix-511 (Nippi) in StemFit AK02 medium (Ajinomoto). All cells were cultured at 37C in a humidified atmosphere containing 5% CO2 and 95% air.

Differentiation of hiPSCs into NS/PCs was induced, as previously reported, with a few modifications. For adhesive differentiation, hiPSCs were detached through incubation with StemPro Accutase (Thermo Fisher Scientific) containing 10M Y-27632 for 10min and seeded onto 24-well cell culture plates (BD Biosciences) coated with iMatrix at a density of 25,000 cells/cm2 for 23days before NS/PC induction. Confluent hiPSCs were treated with 10M of the ALK inhibitor SB431542 (Stemgent) and 500ng/mL of Noggin (R&D systems) in DMEM/F12 medium containing 20% KSR. The medium was replaced on days 1 and 2. On day 6 of differentiation, SB431542 was withdrawn, and increasing amounts of N2 media (25%, 50%, and 75%) were added to the knockout serum replacement medium every 2days while maintaining 500ng/mL of Noggin. For suspension differentiation, hiPSCs were treated with 10M Y-27632 for 1h at 37C and dissociated with StemPro Accutase (Thermo Fisher Scientific) containing 10M Y-27632 for 10min to generate single-cell suspensions and suspended in B27N2-based medium [DMEM/F12 with 15mM HEPES, 5% B27, and 5% N2 supplements (Life Technologies), 10M SB431542, 2M Dorsomorphin (Fujifilm), and 10ng/mL bFGF (R&D systems)]. The completely dissociated cells were seeded into ultralow attachment 96-well plates (PrimeSurface 96-well, Sumitomo Bakelite) at 9,000 cells/well, centrifuged at 700g for 3min (quick aggregation). The medium was changed daily for up to 10days; for the first 3days, 10M of Y-27632 was added. Total RNA was obtained from 40 wells of neuro spheres per sample. For microarray analysis, hiPSCs were differentiated into NS/PCs using a STEMdiff SMADi Neural Induction Kit (Stem Cell Technologies) according to the manufacturers instructions. Briefly, hiPSCs were maintained on an iMatrix-coated plate in StemFitAK02 media (Ajinomoto) before NS/PC induction. Cells were harvested using Accutase (Thermo Fisher Scientific); 2106 cells were transferred to a Matrigel-coated 6-well plate in STEMdiff Neural Induction Medium+SMADi (Stem Cell Technologies) supplemented with 10M Y-27632. The medium was replenished daily with warmed (37C) STEMdiff Neural Induction Medium+SMADi until the culture was terminated. Cells were passaged every 7days, and RNA was extracted from cells harvested at passages (days 7, 14, and 21).

Total RNA was isolated from hiPSCs or differentiated cells using the RNeasy Mini Kit (Qiagen) and treated with DNase I according to the manufacturers instructions. qRT-PCR was performed using a QuantiTect Probe One-Step RT-PCR Kit (Qiagen) on a STEPONEPLUS Real-Time PCR System (Applied Biosystems). The expression levels of target genes were normalized to those of the GAPDH transcript or 18S rRNA, which were quantified using TaqMan human Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) control reagents (Applied Biosystems) or eukaryotic 18S rRNA endogenous controls (Applied Biosystems), respectively. The probes and primers were obtained from Sigma-Aldrich. The used primer and probe sequences are listed in Supplementary Table 2. PCA was performed using SYSTAT 13 software (Systat Software Inc.) after data standardization (z-scoring) for each NS/PC marker gene.

To identify microarray probe sets related to the differentiation of hiPSCs into NS/PC, correlations between the intensity value rank of the filtered probe sets and the PC1 rank in the 10 hiPSC lines were determined by calculating Spearmans rank correlation coefficients (rs), as described in a previous study26. Probe sets exhibiting statistically significant correlations (P<0.01) were selected. When n=10 data points, the observed value of rs should exceed 0.794 (positively correlated) or less than 0.794 (negatively correlated) to be considered statistically significant (P<0.01).

ROR2 KD cells were generated by infecting R-2A cells with MISSION Lentiviral Transduction Particle expressing ROR2-targeted shRNAs (#1: TRCN0000199888, #2: TRCN0000001492) or MISSIONpLKO.1-puro Control Non-Mammalian shRNA Control Transduction Articles (Sigma, SHC002V), according to the manufacturers instructions. Media containing viruses were collected 48h after transfection, and the cells were transduced with the viruses using 8g/mL polybrene (Sigma-Aldrich) for 24h. The cells were selected using 2g/mL puromycin (Gibco) for 48h.

The cell lysates were used for western blotting analysis. Proteins were separated using sodium dodecyl sulfatepolyacrylamide gel electrophoresis, transferred to PVDF membranes (Bio-Rad), and blocked for 60min in Blocking One (Nacalai tesque). Primary antibody dilutions were prepared in Can Get Signal immunoreaction enhancer solution (TOYOBO) as follows: anti-ROR2 antibody (AF2064; R&D Systems) 1:1000, anti--actin antibody (A5441; Sigma-Aldrich) 1:2000. Membranes were incubated with HRP-conjugated anti-mouse IgG (Invitrogen) or anti-goat IgG (Invitrogen). Proteins were visualized using ECL Prime Western Blotting Detection Reagent (GE Healthcare) and the ChemiDoc Touch Imaging System (Bio-Rad).

HiPSC-derived NS/PC or forebrain neuron was fixed in 4% paraformaldehyde in PBS (Nacalai) for 20min at 25C. After washing with PBS, the cells were permeabilized with 0.2% Triton-X100 (Merk) in PBS for 15min and blocked with Blocking One (Nacalai) for 30min. The samples were incubated for 1h with primary antibodies (anti-PAX6 antibody [PRB-278P-100, BioLegend], anti-MAP2 antibody [MAB8304, R&D systems], and anti-GAD1 antibody [AF2086, BioLegend]). Indirect immunostaining was performed with the secondary antibody (anti-rabbit IgG/Alexa Fluor 555 [A27039, Thermo Fisher Scientific], anti-goat IgG/Alexa Fluor 488 [A32814, Thermo Fisher Scientific], and anti-mouse IgG/Alexa Fluor 488 [A28175, Thermo Fisher Scientific]) for 1h and examined under a BZ-X810 fluorescence microscope (Keyence).

ROR2 overexpression cells were generated by infecting 253G1 cells with lentiviral particles expressing ROR2. Briefly, the nucleotide sequence of the human ROR2 open reading frame (NM_004560) was de novo synthesized (Eurofins Genomics) and cloned into the pLVSIN-EF1 puromycin vector (Takara Clontech). Lentivirus packaging and virus infection were performed as described above.

Total RNA was extracted from hiPSC-derived NS/PC cells using an RNeasy Mini Kit (QIAGEN) according to the manufacturers instructions. Total RNA (100ng per sample) was used as the input for the Clariom D Assay (Thermo Fisher Scientific). Target preparation was performed using a Gene Chip WT PLUS Reagent Kit (Thermo Fisher Scientific) according to the manufacturers instructions. Hybridization was performed in a Gene Chip Hybridization Oven 645 for 16h at 45C. Gene chips were scanned using a GeneChip Scanner 3000. Array quality control was performed using Transcriptome Analysis Console software (version 4.0.2.15). The National Center for Biotechnology Information Gene Expression Omnibus (NCBI GEO) accession number for the microarray data is GSE233228.

Differentiation of hiPSCs into mature nerves was performed according to the manufacturers instructions using the STEMdiff Forebrain Neuron Differentiation Kit (#08600, STEMCELL Technologies) for forebrain-type nerves and the STEMdiff Midbrain Neuron Differentiation Kit (#100-0038, STEMCELL Technologies) for midbrain nerves. Using the STEMdiff SMADi Neural Induction Kit (Stem Cell Technologies) monolayer culture protocol described above, hiPSCs were differentiated into NS/PC, and mature neural differentiation was induced.

For midbrain neuron differentiation, hiPSC-derived NS/PCs (day21, passage 3) were detached using Accutase and seeded into PLO (Sigma)-and laminin (Sigma)-coated 12-well plate at a density of 1.25105 cells/cm2 culture in STEMdiff Neural Induction Medium+SMADi medium for 24h. The complete medium was replaced daily for 6days with STEMdiff Midbrain Neuron Differentiation Medium. The midbrain neural precursors (day 7) were detached using ACCUTASE and seeded into PLO-and Laminin-coated 12-well plate at a density of 5104 cells/cm2 in STEMdiff Midbrain Neuron Maturation medium with a half-medium change every 23days for 14days.

For forebrain-type neuron differentiation, hiPSC-derived NS/PCs (day21, passage 3) were detached using Accutase and then seeded into PLO-and Laminin-coated 12-well plate at a density of 1.25105 cells/cm2 culture in STEMdiff Neural Induction Medium+SMADi medium for 24h. The full medium was replaced daily for 6days with STEMdiff Forebrain Neuron Differentiation medium. The forebrain neural precursors (day7) were detached using Accutase and seeded into PLO- and Laminin-coated 12-well plate at a density of 5104 cells/cm2 in STEMdiff Forebrain Neuron Maturation media with a half-medium change every 23days for 14days.

Statistical analyses were performed using Prism 9 software (version 9.5.1; GraphPad Software Inc.). Data are presented as meanstandard deviation (SD). For comparison between two groups the t-test was applied; in cases where another statistic test was applied, it is mentioned accordingly. Statistical significance was set at P<0.05.

Original post:
ROR2 expression predicts human induced pluripotent stem cell differentiation into neural stem/progenitor cells and ... - Nature.com

Consumers should beware of stem cell treatments for Covid-19 – BioEdge

By adminJanuary 8, 2024Stem Cell Clinics

A recent analysis has identified 38 companies offering so-called stem cell treatments and exosome treatments for preventing as well as treating COVID. These interventions are not supported by convincing safety and efficacy data; they have not been authorised by regulatory bodies such as the Food and Drug Administration (FDA).

The study, led by Professor Leigh Turner, from University of California, Irvine, also found that some of these dubious businesses are claiming to treat long Covid. This is often a debilitating condition that has no proven treatments at present. Some patients with long Covid may have physical symptoms including brain fog, fatigue and headaches that persist for months or possibly years. Desperate patients are extremely vulnerable to misleading claims made by such unscrupulous businesses due to the seriousness of the symptoms they are suffering.

As the human bodys master cells, stem cells have tremendous potential to repair and regenerate cells. However, these therapies have not been approved by regulatory groups. The FDA approved stem cell treatments for only some blood disorders but not for any other medical condition.

In 2021, the early days of the pandemic, Turner published a study regarding 1,480 American businesses promoting unlicensed stem cell-based interventions, some of which even claimed to prevent and treat Covid-19. In the present study, the companies continue to make those same claims while adding claims about long Covid; 36 of the 38 businesses in this analysis stated they had treatments for it. Six companies promoted them as immune boosters, five claimed to treat patients in the acute stage and two businesses stated their products were preventive. As means of advertising their products, some businesses resorted to social media like Facebook, Instagram, Twitter and TikTok. There were also promotional videos on YouTube.

The 38 companies are either operating or facilitating access to 60 clinics. Of the 60 clinics, 24 operate in the US and 22 in Mexico. Other clinics are in Ukraine, Guatemala, Malaysia, Panama, the Philippines, Poland, Spain, Thailand and the United Arab Emirates (UAE). Many of these treatments are costly between US$2,950 and $25,000. Some prices were stated as minimum costs, which suggests that the real expenses might be much more. Health insurance coverage generally does not cover stem cell interventions.

It is critical to have strict oversight as well as enforcement of the existing law. Regulatory bodies, such as the FDA and FTC (Federal Trade Commission) need to play their part enforcing the regulation. The FDAs Center for Biologics Evaluation and Research (CBER) is tasked with regulating cells, tissues and cellular and tissue-based products (HCT/P) which are intended for implantation, transplantation, infusion or transfer into a recipient. The agency has published detailed documents (good tissue practice, donor screening and donor testing requirements), to prevent the introduction, transmission and spread of communicable disease.

The FTC should pursue enforcement action against the clinics based on its jurisdiction over consumer protection issues such misleading and deceptive advertising. This agencys aims include the promotion of competition as well asprotecting and educating consumers. The commission should pursue a legal action when it has reason to believe that the violators are breaking or are about to break the law and it appears that bringing a lawsuit is needed as it is in the public interest. These federal bodies must implement various enforcement steps against these unscrupulous stem cell clinics. The measures should include warning letters and untitled letters and even suing these businesses.

There is at least one case that involves a lawsuit brought against a clinic that promoted stem cell products are treatments for Covid. In State of Washington v. US Stemology LLC and Tami Meraglia, it was alleged that US Stemology violated the states consumer protection legislation by deceptively promoting stem cell treatments of severe conditions, including Covid-19, without scientific basis. These claims were made at the start of the pandemic. A promotion from the company mentioned that a critically ill Covid patient recovered from the treatments. It also claimed a Free Coronavirus Thriving Guide that called stem cell treatment your personalised vaccine against getting sick with Covid-19.It stated, The reason for this is because stem cell therapy treats the lungs first and has long-term anti-inflammatory and immune modulating properties. Ultimately, the parties reached a settlement the company would pay $500,000 to the Attorney Generals Office, whichwill be distributed to the patients.

On a positive note, the National Institutes of Health (NIH) has begun several clinical trials on treating long Covid. Also the FDA has authorised stem cell clinical trials for long Covid. There has been a worrying surge of cases during this holiday period. Thus, patients with Covid, especially those with long Covid, need to shun these unscrupulous clinics peddling dubious treatments. Equally important, the various enforcement agencies need to do their part.

*******

Dr Patrick Foong is a senior law lecturer at Western Sydney University. His research interest lies in bioethics and health law.

Dr Alan W. Leung was a junior faculty at Yale University and Nationwide Childrens Hospital, and led iPSC product development at CRISPR therapeutics and Elevatebio. He is currently a freelance life science consultant and writer. His research interest lies in human embryonic stem cell therapy and preclinical applications.

Dr Patrick Foong is a senior law lecturer at Western Sydney University. His research interest lies in bioethics and health law.

Read the original here:
Consumers should beware of stem cell treatments for Covid-19 - BioEdge

Majority Leader Scalise to miss all of January as he undergoes stem cell treatment – Washington Examiner

By adminJanuary 8, 2024Stem Cell Treatment

House Majority Leader Steve Scalise (R-LA) will not return to Washington, D.C., until February as he undergoes a stem cell transplant as part of his cancer treatment, his office announced on Friday.

Last year, Scalise was diagnosed with multiple myeloma and underwent chemotherapy, which he completed in December. According to his office, Scalise had a positive response to the treatment and became eligible for an autologous stem cell transplant.

GOP TO PRESS FAUCI ON HANDLING OF SCIENTIFIC DEBATE IN FIRST POST-RETIREMENT TESTIMONY

He is currently undergoing the transplant process, marking a significant milestone in his battle against cancer. Once the procedure is completed, he will be recovering under the supervision of his medical team and will work remotely until returning to Washington next month. He is incredibly grateful to have progressed so well, and is thankful to his entire medical team, family, friends, and colleagues for their prayers and support, his office said in a statement.

With Scalise being gone for the month of January, it further dwindles House Republicans already slim majority during a month in which they are faced with a battle over must-pass legislation.

CLICK HERE TO READ MORE FROM THE WASHINGTON EXAMINER

When the House returns on Jan. 9, lawmakers will immediately be tasked with passing government funding, some of which will expire on Jan. 19.

Currently, House Republicans have a 220-seat majority. That will drop to 219 with Scalise gone and 218 when Rep. Bill Johnson (R-OH) leaves on Jan. 21. This will make it that much harder for leadership to pass legislation, which it was already struggling to get through the lower chamber.

Excerpt from:
Majority Leader Scalise to miss all of January as he undergoes stem cell treatment - Washington Examiner